Business
Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company
About this update from Genprex, Inc.
[{"type":"text","content":" AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nGenprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, announced today that it closed its previously announced common stock offering priced at-the-market under Nasdaq rules. The Company sold an aggregate of 5,000,000 shares of its common stock at a price of $3.50 per share for gross proceeds to the Company of $17.5 million, before deducting commissions and estimated offering expenses. There were no warrants issued in the offering.\n\n\nA.G.P./Alliance Global Partners acted as the lead placement agent for the offering, and Joseph Gunnar & Co., LLC acted as co-placement agent for the offering.\n\n\nThe Company intends to use the net proceeds from the offering to advance its drug development programs and for working capital and general corporate purposes.\n\n\n“The successful closing of this transaction is further evidence that our corporate vision and proprietary technology in the gene therapy cancer treatment market are gaining traction with institutional investors,” commented Rodney Varner, Chief Executive Officer at Genprex. “This offering will provide additional resources for further development of our technologies, including the planned clinical trial of our Oncoprex™ immunogene therapy in combination with osimertinib (marketed as Tagrisso® by Astra Zeneca) for which we recently received a U.S. FDA Fast Track Designation, and our planned clinical trial of Oncoprex immunogene therapy combined with pemrolizumab (marketed as Keytruda by Merck & Co), both in non-small cell lung cancer, as well as further development of our pre-clinical gene therapy for Type 1 and Type 2 diabetes which we recently in-licensed from the University of Pittsburgh. We are excited to advance these new drug candidates toward potential availability for treatment of these serious diseases in large patient populations with unmet medical needs.”\n\n\nThe securities were offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-233774) previously filed and declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on October 28, 2019 and an additional registration statement on Form S-3 (File No. 333-236504) ...